Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT07802704 |
| Title | A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302] |
| Acronym | EMBOLD Prostate-302 |
| Recruitment | Recruiting |
| Gender | male |
| Phase | Phase III |
| Variant Requirements | Yes |
| Sponsors | GlaxoSmithKline |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | CAN | AUS |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| GSK Investigational Site | RECRUITING | Auchenflower | Queensland | 4066 | Australia | Details |
| GSK Investigational Site | RECRUITING | Montreal | Quebec | H4A 0B1 | Canada | Details |
| GSK Investigational Site | RECRUITING | Tokyo | 135-8550 | Japan | Details | |
| GSK Investigational Site | RECRUITING | Tottori | 683-8504 | Japan | Details | |
| GSK Investigational Site | RECRUITING | Seoul | Seoul Teugbyeolsi | 3080 | South Korea | Details |
| GSK Investigational Site | RECRUITING | Gyeonggi-do | 10408 | South Korea | Details |